Logo image
Back
Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions
Journal article   Open access   Peer reviewed

Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions

Harma Ellens, Shibing Deng, JoAnn Coleman, Joe Bentz, Mitchell E. Taub, Isabelle Ragueneau-Majlessi, Sophie P. Chung, Krisztina Heredi-Szabo, Sibylle Neuhoff, Johan Palm, …
Drug metabolism and disposition, v 41(7), pp 1367-1374
01 Jul 2013
DOI: https://doi.org/10.1124/dmd.112.050542
PMID: 23620486
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1124/dmd.112.050542View
Published, Version of Record (VoR)Open Access (License Unspecified),  Open

Abstract

Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology
In the 2012 Food and Drug Administration (FDA) draft guidance on drug-drug interactions (DDIs), a new molecular entity that inhibits P-glycoprotein (P-gp) may need a clinical DDI study with a P-gp substrate such as digoxin when the maximum concentration of inhibitor at steady state divided by IC50 ([I-1]/IC50) is >= 0.1 or concentration of inhibitor based on highest approved dose dissolved in 250 ml divide by IC50 ([I-2]/IC50) is >= 10. In this article, refined criteria are presented, determined by receiver operating characteristic analysis, using IC50 values generated by 23 laboratories. P-gp probe substrates were digoxin for polarized cell-lines and N-methyl quinidine or vinblastine for P-gp overexpressed vesicles. Inhibition of probe substrate transport was evaluated using 15 known P-gp inhibitors. Importantly, the criteria derived in this article take into account variability in IC50 values. Moreover, they are statistically derived based on the highest degree of accuracy in predicting true positive and true negative digoxin DDI results. The refined criteria of [I-1]/IC50 >= 0.03 and [I-2]/IC50 >= 45 and FDA criteria were applied to a test set of 101 in vitro-in vivo digoxin DDI pairs collated from the literature. The number of false negatives (none predicted but DDI observed) were similar, 10 and 12%, whereas the number of false positives (DDI predicted but not observed) substantially decreased from 51 to 40%, relative to the FDA criteria. On the basis of estimated overall variability in IC50 values, a theoretical 95% confidence interval calculation was developed for single laboratory IC50 values, translating into a range of [I-1]/IC50 and [I-2]/IC50 values. The extent by which this range falls above the criteria is a measure of risk associated with the decision, attributable to variability in IC50 values.

Metrics

13 Record Views
40 citations in Web of Science
44 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Web of Science research areas
Pharmacology & Pharmacy
Logo image